Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) missed Wall Street’s revenue expectations in Q4 CY2024, but ...

Q4 2024 Earnings Call Transcript February 18, 2025 NeoGenomics, Inc. beats earnings expectations. Reported EPS is $0.04, ...

NEOGENOMICS ($NEO) posted quarterly earnings results on Tuesday, February 18th. The company reported earnings of $0.04 per share, beating estimates of $0.03 by $0.01 ...

Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 21.5% in the afternoon session after the ...

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting results tomorrow morning. Here’s what to ...

NeoGenomics Inc (NEO) reports robust revenue growth and improved margins, while navigating challenges in the pharma segment and ongoing litigation.

NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) hit a new 52-week low during mid-day trading on Tuesday after the company announced weaker than expected quarterly earnings.The company traded as ...

Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 21.5% in the afternoon session after the company reported weak fourth-quarter results, with revenue falling below Wall ...

NASDAQ:NEO opened at $14.42 on Monday. NeoGenomics has a 1 year low of $12.13 and a 1 year high of $19.11. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.91 and a current ratio ...

For the upcoming fiscal year 2025, NeoGenomics anticipates an EPS of $0.15 to $0.19, compared to the consensus projection of $0.20. The company's revenue forecast for FY2025 stands at $735-745 million ...